THE ARISING · DAILY EDITION
The Arising — October 15, 2026
Download the PDF ↓Longevity & Healthspan
Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women
Midlife women who took menopause hormone therapy while on semaglutide lost more weight than those who did not, according to The Menopause Society's report of a new study. The finding is an association, and the lead researcher says it is too early to act on it.
GLP-1 medicines →Falling Cardiolipin Levels May Explain Why Aging Muscles Lose Power
Aging muscle has a puzzle at its core: as mitochondria, the cell's energy units, work less well, muscle shifts toward fibers that rely on them more. A new study in Nature Aging suggests a single fat in the mitochondrial membrane, called cardiolipin, may explain why.
Strength and function →Swedish 47-Year Study: Aerobic Fitness and Endurance Peak Between 26 and 36
Physical capacity in ordinary adults appears to peak between the mid20s and mid-30s and then slowly fall, according to a 47-year Swedish study in the Journal of Cachexia, Sarcopenia and Muscle. Strength was not tracked across the decades; the study followed aerobic capacity, muscular endurance and leg power, with grip strength measured only at 63. Press coverage describes the finding as 'fitness and strength' declining around 35, but the paper's peaks range from 26 to 36.
Strength and function →Gene SRSF1 Made Aged Cells Look Younger; Linked to Longer Mouse Life
Turning up a single gene made aged human skin cells look and behave more like young ones, and in old mice it was linked to slower decline and a longer median life, according to a new study in Nature Aging. The lifespan finding is an association, not proof that the gene extends life, and the mouse groups were small.
Strength and function →Scans of 100,000 Patients Link Active Brown Fat to Better Metabolic Health
People who carry active brown fat tend to have healthier blood sugar, cholesterol and hearts. A large new analysis suggests they may also have lower rates of psychiatric disease. But the finding shows a link, not a cause, and it does not mean anyone should start a blood pressure drug to get more of this tissue.
Care and connection →
Markets & Strategy
Regeneron Plans Trial in Older Adults After Muscle-Sparing Antibody Preserves Lean Mass
Regeneron is betting that the next way to stand out in the crowded GLP-1 market is not more weight loss, but better weight loss, and it has picked older adults as the place to test that idea.
GLP-1 medicines →BDT & MSD to Buy Sunrise Senior Living From PSP Investments
An investment firm known for hotels, resorts and apartment operators has agreed to take control of one of the best-known names in senior living, and the deal tests whether hospitality skills can win in a care-driven business. The release cites no earlier senior housing holdings for the buyer, but it does not say whether this is its first such investment.
Care and connection →Whoop Moves From Athletes to Medicare Seniors Through Outcome-Based ACCESS Pilot
Whoop built its brand on performance athletes. Now it is asking Medicare to tie its full payment to whether older patients' health measures improve or stay controlled.
Care and connection →Typical Medicare Beneficiary Loses Four Advantage Drug Plan Options for 2027
The average Medicare beneficiary will have 28 Medicare Advantage prescription drug plans to choose from in 2027, down from 32 in 2026, according to a KFF analysis published October 1.
Care and connection →CMS Finalizes Narrowed GLOBE Model Benchmarking Part B Drugs to Foreign Prices
Medicare's plan to tie Part B drug rebates to foreign prices just shrank from a sweeping program to a narrow one. According to Covington & Burling, the federal government now projects $440 million in net Part B savings from the GLOBE Model, down from $11.9 billion in the proposal.
Care and connection →